Information Provided By: 
Fly News Breaks for May 27, 2015
BLUE, FPRX
May 27, 2015 | 07:48 EDT
After Five Prime (FPRX) announced an exclusive license agreement with Bluebird Bio (BLUE) for the development and commercialization of CAR-Ts under which Five Prime will provide bluebird exclusive rights to its antibodies, Oppenheimer says the deal further validates the strength of Five Prime's functional discovery platform. The firm thinks that additional tests of CAR-T are likely to drive further demand for Five Prime's discovery platform. It keeps a $45 price target and Outperform rating on Five Prime.
News For FPRX;BLUE From the Last 2 Days
There are no results for your query FPRX;BLUE
